Endogenous purinergic signaling is required for osmotic volume regulation of retinal glial cells

J Neurochem. 2010 Mar;112(5):1261-72. doi: 10.1111/j.1471-4159.2009.06541.x. Epub 2009 Dec 10.

Abstract

Intense neuronal activity in the sensory retina is associated with a volume increase of neuronal cells (Uckermann et al., J. Neurosci. 2004, 24:10149) and a decrease in the osmolarity of the extracellular space fluid (Dmitriev et al., Vis. Neurosci. 1999, 16:1157). Here, we show the existence of an endogenous purinergic mechanism that prevents hypoosmotic swelling of retinal glial (Müller) cells in mice. In contrast to the cells from wild-type mice, hypoosmotic stress induced rapid swelling of glial cell somata in retinal slices from mice deficient in P2Y(1), adenosine A(1) receptors, or ecto-5'-nucleotidase (CD73). Consistently, glial cell bodies in retinal slices from wild-type mice displayed osmotic swelling when P2Y(1) or A(1) receptors, or CD73, were pharmacologically blocked. Exogenous ATP, UTP, and UDP inhibited glial swelling in retinal slices, while the swelling of isolated glial cells was prevented by ATP but not by UTP or UDP, suggesting that uracil nucleotides indirectly regulate the glial cell volume via activation of neuronal P2Y(4/6) and neuron-to-glia signaling. It is suggested that autocrine/paracrine activation of purinergic receptors and enzymes is crucially involved in the regulation of the glial cell volume.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 5'-Nucleotidase / deficiency
  • Adenine / analogs & derivatives
  • Adenine / pharmacology
  • Adenosine Diphosphate / analogs & derivatives
  • Adenosine Diphosphate / pharmacology
  • Animals
  • Barium Compounds / metabolism
  • Calcium / metabolism
  • Cell Size*
  • Chlorides / metabolism
  • Cyclic AMP / metabolism
  • Drug Combinations
  • Enzyme Inhibitors / pharmacology
  • In Vitro Techniques
  • Inositol 1,4,5-Trisphosphate Receptors / deficiency
  • Mice
  • Mice, Knockout
  • Neuroglia / cytology*
  • Neuroglia / drug effects
  • Neurons / drug effects
  • Neurons / metabolism
  • Osmolar Concentration
  • Osmosis*
  • Potassium Channel Blockers / pharmacology
  • Purinergic Agonists
  • Purinergic Antagonists
  • Pyrimidine Nucleotides / pharmacology
  • Quaternary Ammonium Compounds / pharmacology
  • Receptors, Purinergic / deficiency
  • Receptors, Purinergic / metabolism*
  • Retina / cytology*
  • Signal Transduction / drug effects
  • Signal Transduction / genetics
  • Signal Transduction / physiology*
  • Thionucleotides / pharmacology
  • Time Factors
  • Valerates / pharmacology
  • Xanthines / pharmacology

Substances

  • 2,2-dimethylpropionic acid 3-(2-chloro-6-methylaminopurin-9-yl)-2-(2,2-dimethylpropionyloxymethyl)propyl ester
  • Barium Compounds
  • Chlorides
  • Drug Combinations
  • Enzyme Inhibitors
  • Inositol 1,4,5-Trisphosphate Receptors
  • N(6)-methyl-2'-deoxyadenosine 3',5'-diphosphate
  • Potassium Channel Blockers
  • Purinergic Agonists
  • Purinergic Antagonists
  • Pyrimidine Nucleotides
  • Quaternary Ammonium Compounds
  • Receptors, Purinergic
  • Thionucleotides
  • Valerates
  • Xanthines
  • barium chloride
  • adenosine 5'-O-(1-thiodiphosphate)
  • Adenosine Diphosphate
  • clofilium
  • 1,3-dipropyl-8-cyclopentylxanthine
  • Cyclic AMP
  • 5'-Nucleotidase
  • Adenine
  • Calcium